Saudi Chemical Holding Company and its Subsidiaries (A Saudi Joint Stock Company)

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AND INDEPENDENT AUDITOR'S REVIEW REPORT

FOR THE THREE AND NINE-MONTHS PERIODS ENDED 30 SEPTEMBER 2026

Saudi Chemical Holding Company and its Subsidiaries
(A Saudi Joint Stock Company)

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
30 September 2026

INDEX	***PAGE***
Independent Auditor's Review Report	1
Interim Condensed Consolidated Statement of Financial Position	2
Interim Condensed Consolidated Statement of Comprehensive Income	3
Interim Condensed Consolidated Statement of Changes in Equity	4
Interim Condensed Consolidated Statement of Cash Flows	5
Notes to the Interim Condensed Consolidated Financial Statements	6-20

Ernst & Young Professional Services (Professional LLC)
Paid-up capital (﷼ 5,500,000 – Five million five hundred thousand Saudi Riyal)

Head Office
Financial Boulevard 3126, Al Aqeeq Dist. 6717, Riyadh 13519
KAFD 1.11 B, South Tower, 8th Floor
P.O. Box 2732, Riyadh 11461
Kingdom of Saudi Arabia

C.R. No.: 1010383821
Unified No.: 7000117205

Tel: +966 11 215 9898
+966 11 273 4740
Fax: +966 11 273 4730

ey.ksa@sa.ey.com
ey.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS TO THE SHAREHOLDERS OF SAUDI CHEMICAL HOLDING COMPANY (A SAUDI JOINT STOCK COMPANY)

Introduction

We have reviewed the accompanying interim condensed consolidated statement of financial position of Saudi Chemical Holding Company – a Saudi Joint Stock Company (the "Company") and its subsidiaries (collectively referred to as the "Group") as at 30 September 2026, and the related interim condensed consolidated statement of comprehensive income for the three-month and nine-month periods ended 30 September 2026, and the related interim condensed consolidated statements of changes in equity and cash flows for the nine-month period then ended, and explanatory notes. Management is responsible for the preparation and presentation of these interim condensed consolidated financial statements in accordance with International Accounting Standard 34, "Interim Financial Reporting" ("IAS 34") as endorsed in the Kingdom of Saudi Arabia. Our responsibility is to express a conclusion on these interim condensed consolidated financial statements based on our review.

Scope of Review

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" as endorsed in the Kingdom of Saudi Arabia. A review of interim financial statement consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing that are endorsed in the Kingdom of Saudi Arabia and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying interim condensed consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34 as endorsed in the Kingdom of Saudi Arabia.

for Ernst & Young Professional Services

Hesham A. Alatiqi
Certified Public Accountant
License No. 523

R7
سجل تجاري ١٠١٠٣٨٣٨٢١
CR.1010383821
شركة إرنست ويونغ للخدمات المهنية
(مهنية ذات مسؤولية محدودة)
Ernst & Young Professional Services
(Professional LLC)

Riyadh: 25 Jumada al-Ula 1448H
(5 November 2026)

Docusign Envelope ID: E43FDFFC-E74D-8FE2-80FA-4FC58D010D50

Saudi Chemical Holding Company and its Subsidiaries
(A Saudi Joint Stock Company)
INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
As at 30 September 2026

	Notes	*30 September 2026* ﷼ *'000* *(Unaudited)*	*31 December 2025* ﷼ *'000* *(Audited)*
Assets			
Non-current assets			
Property, plant and equipment	3.1	**932,154**	609,346
Capital work in progress	3.2	**196,948**	497,145
Intangible assets and goodwill	3.3	**622,264**	620,317
Right of use assets		**42,236**	47,377
Derivative financial instruments	4	**5,948**	329
Total non-current assets		**1,799,550**	1,774,514
Current assets			
Inventories		**1,601,678**	1,543,038
Trade receivables	5	**2,849,845**	2,631,474
Prepayments and other current assets		**316,510**	161,541
Amounts due from a related party	6	**3,816**	6,942
Cash and cash equivalents		**130,254**	117,501
Total current assets		**4,902,103**	4,460,496
Total assets		**6,701,653**	6,235,010
Liabilities and equity			
Equity			
Share capital	7	**843,200**	843,200
Statutory reserve		**341,868**	341,868
General reserve		**340,000**	340,000
Retained earnings		**1,005,831**	857,786
Equity attributable to equity holders of the parent		**2,530,899**	2,382,854
Non-controlling interests		**16,137**	14,257
Total Equity		**2,547,036**	2,397,111
Liabilities			
Non-current liabilities			
Long term Islamic loans – non-current	8.3	**141,176**	194,118
Saudi Industrial Development Fund's financing – non-current	8.1	**195,476**	251,492
Lease liabilities – non-current		**31,621**	31,296
Employee's defined benefit liabilities		**80,976**	75,501
Government grants		**125**	1,255
Total non-current liabilities		**449,374**	553,662
Current liabilities			
Saudi Industrial Development Fund's financing – current	8.1	**58,298**	50,935
Lease liabilities – current		**9,094**	15,952
Long-term loans – current	8.3	**111,569**	134,902
Short-term Islamic loans	8.2	**668,955**	504,454
Trade payables		**2,570,534**	2,307,005
Accrued expenses and other liabilities		**203,438**	182,215
Government grant		**1,506**	1,506
Zakat and income tax payable	10	**68,589**	74,008
Dividends payable		**13,260**	13,260
Total current liabilities		**3,705,243**	3,284,237
Total liabilities		**4,154,617**	3,837,899
Total Equity and Liabilities		**6,701,653**	6,235,010

Abdullah Almehthil
Group CFO

Eng. Abdulsalam Al-Ghamdi
Group CEO

Fawaz Al-Fawaz
Chairman of Board of Directors

The attached notes 1 to 18 form an integral part of these interim condensed consolidated financial statements.

Docusign Envelope ID: E43FDFFC-E74D-8FE2-80FA-4FC58D010D50

Saudi Chemical Holding Company and its Subsidiaries
(A Saudi Joint Stock Company)
INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (UNAUDITED)
For the three and nine-months periods ended 30 September 2026

	Notes	*For the three-month period ended 30 September*		*For the nine-month period ended 30 September*	
		2026 ﷼ *'000*	*2025* ﷼ *'000*	*2026* ﷼ *'000*	*2025* ﷼ *'000*
Revenues	9	**1,697,542**	1,788,072	**5,266,593**	5,197,413
Cost of revenues		**(1,502,081)**	(1,559,645)	**(4,659,687)**	(4,550,520)
Gross profit		**195,461**	228,427	**606,906**	646,893
Selling and distribution expenses		**(47,708)**	(52,584)	**(128,160)**	(123,020)
General and administrative expenses		**(40,292)**	(38,260)	**(119,247)**	(113,981)
Expected credit loss on trade receivables	5	**(12,352)**	(12,637)	**(41,511)**	(58,047)
Operating profit		**95,109**	124,946	**317,988**	351,845
Finance cost		**(18,418)**	(28,035)	**(52,495)**	(78,271)
Finance income		**552**	751	**2,225**	1,363
Other income, net		**177**	609	**1,834**	2,030
Foreign currency exchange losses		**(89)**	(49)	**102**	(31)
Revaluation gain (loss) on derivative financial instruments	4	**1,715**	761	**5,619**	(1,414)
Profit before zakat and income tax		**79,046**	98,983	**275,273**	275,522
Zakat and income tax expenses	10	**(13,925)**	(11,607)	**(41,028)**	(35,070)
Net profit for the period		**65,121**	87,376	**234,245**	240,452
Other comprehensive income for the period		**-**	-	**-**	-
Total comprehensive income for the period		**65,121**	87,376	**234,245**	240,452
Net profit for the period attributable to:					
Equity holders of the parent		**64,590**	87,240	**232,365**	238,474
Non-controlling interests		**531**	136	**1,880**	1,978
		65,121	87,376	**234,245**	240,452
Basic and diluted earnings per share (﷼)	11	**0.08**	0.10	**0.28**	0.28

Abdullah Almehthil
Group CFO

Eng. Abdulsalam Al-Ghamdi
Group CEO

Fawaz Al-Fawaz
Chairman of Board of Directors

The attached notes 1 to 18 form an integral part of these interim condensed consolidated financial statements.

Docusign Envelope ID: E43FDFFC-E74D-8FE2-80FA-4FC58D010D50

Saudi Chemical Holding Company and its Subsidiaries
(A Saudi Joint Stock Company)
INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
For the nine-month period ended 30 September 2026

	Attributable to the equity holders of the parent						
	Share capital ﷼ '000	*Statutory reserve* ﷼ '000	*General reserves* ﷼ '000	*Retained earnings* ﷼ '000	*Total* ﷼ '000	*Non-controlling interests* ﷼ '000	*Total equity* ﷼ '000
At 31 December 2024 (Audited)	843,200	341,868	340,000	565,870	2,090,938	11,577	2,102,515
Net profit for the period	-	-	-	238,474	238,474	1,978	240,452
Other comprehensive income for the period	-	-	-	-	-	-	-
Total comprehensive income for the period	-	-	-	238,474	238,474	1,978	240,452
Dividends (note 15)	-	-	-	(42,160)	(42,160)	-	(42,160)
At 30 September 2025 (Unaudited)	843,200	341,868	340,000	762,184	2,287,252	13,555	2,300,807
At 31 December 2025 (Audited)	**843,200**	**341,868**	**340,000**	**857,786**	**2,382,854**	**14,257**	**2,397,111**
Net profit for the period	-	-	-	**232,365**	**232,365**	**1,880**	**234,245**
Other comprehensive income for the period	-	-	-	-	-	-	-
Total comprehensive income for the period	-	-	-	**232,365**	**232,365**	**1,880**	**234,245**
Dividends (note 15)	-	-	-	**(84,320)**	**(84,320)**	-	**(84,320)**
At 30 September 2026 (Unaudited)	**843,200**	**341,868**	**340,000**	**1,005,831**	**2,530,899**	**16,137**	**2,547,036**

Abdullah Almehthil
Group CFO

Eng. Abdulsalam Al-Ghamdi
Group CEO

Fawaz Al-Fawaz
Chairman of Board of Directors

The attached notes 1 to 18 form an integral part of these interim condensed consolidated financial statements.

Docusign Envelope ID: E43FDFFC-E74D-8FE2-80FA-4FC58D010D50

Saudi Chemical Holding Company and its Subsidiaries
(A Saudi Joint Stock Company)
INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (UNAUDITED)
For the nine-month period ended 30 September 2026

		For the nine-month period ended 30 September	
		2026	*2025*
		﷼'000	*﷼'000*
Operating activities			
Profit before zakat and income tax		**275,273**	275,522
Adjustments for:			
Amortization of intangible assets	*3.3*	**7,532**	7,117
Depreciation of property, plant and equipment	*3.1*	**36,212**	37,822
Depreciation of right-of-use assets		**7,147**	8,144
(Reversal) / Provision for inventories		**(2,965)**	8,849
Provision for advance to supplier		**1,845**	-
Expected credit loss on trade receivables	5	**41,511**	58,047
Provision for employees' defined benefit obligation		**8,450**	10,618
Revaluation (gain) loss on derivative financial instruments	4	**(5,619)**	1,179
Finance costs		**52,495**	78,271
		421,881	485,569
Working capital changes:			
Inventories		**(55,675)**	49,138
Trade receivables		**(259,882)**	(240,691)
Prepayments and other current assets		**(156,814)**	35,870
Trade payables		**263,529**	176,472
Accrued expenses and other liabilities		**21,223**	(30,964)
Amounts due from / to related parties, net		**3,126**	(119)
Cash generated from operations		**237,388**	475,275
Employees defined benefit obligation paid		**(2,975)**	(4,637)
Zakat and income tax paid	10	**(46,447)**	(37,379)
Finance costs paid		**(46,686)**	(70,510)
Net cash flows generated from operating activities		**141,280**	362,749
Investing activities			
Purchase of property, plant and equipment and capital work in progress		**(65,817)**	(23,990)
Purchase of intangible assets	3.3	**(2,485)**	(2,306)
Net cash flows used in investing activities		**(68,302)**	(26,296)
Financing activities			
Payment of principal portion of lease liabilities		**(11,131)**	(15,505)
Short-term Islamic loans – net		**164,501**	(200,640)
Repayment of long-term loan		**(76,275)**	(23,333)
Repayment of financing from Saudi Industrial Development Fund (SIDF)	8.1	**(53,000)**	(23,500)
Dividends paid to equity holders of the parent	15	**(84,320)**	(42,160)
Net cash flows used in financing activities		**(60,225)**	(305,138)
Net increase in cash and cash equivalents		**12,753**	31,315
Cash and cash equivalents at the beginning of the period		**117,501**	129,525
Cash and cash equivalents at the end of the period		**130,254**	160,840
SIGNIFICANT NON-CASH TRANSACTIONS:			
Transfer from capital work in progress to property, plant, and equipment	3.1	**348,857**	23,256
Transfer from capital work in progress to Intangible assets	3.3	**6,994**	-
Additions to right of use assets and lease liabilities		**-**	13,257

Abdullah Almehthil	**Eng. Abdulsalam Al-Ghamdi**	**Fawaz Al-Fawaz**
Group CFO	**Group CEO**	**Chairman of Board of Directors**

The attached notes 1 to 18 form an integral part of these interim condensed consolidated financial statements.

1 CORPORATE INFORMATION AND ACTIVITIES

Saudi Chemical Holding Company (the "Company") is a Saudi Joint Stock Company registered in Riyadh, Kingdom of Saudi Arabia, under commercial registration number 1010006161 and unified identification number 7006356716 dated 12 Safar 1392H (corresponding to 28 March 1972). The registered office of the Company is: P.O. Box 2665 Riyadh 11461, Kingdom of Saudi Arabia. The Company is listed in Tadawul stock exchange.

The Company and its subsidiaries (collectively referred to as the "Group") are principally engaged in:

- Managing the subsidiaries or participating in the management of other investees and providing the required support for these entities and real estate ownership.
- Manufacturing and selling of explosives and their derivatives for civil or military uses and providing technical support services in explosions.
- Manufacturing, wholesale and retail trading in medicines, medical materials and syrups, pharmaceutical preparations, medical and surgical tools and equipment, supplies of hospitals and medical centers and its related spare parts and food items; and
- Manufacture of ammonium nitrate.

These interim condensed consolidated financial statements include the financial statements of the Company and its following subsidiaries:

			Ownership %	
Subsidiary	***Country of incorporation***	***Main Activity***	***30 September 2026***	*31 December 2025*
Saudi International Trading Company ("SITCO Pharma")	Kingdom of Saudi Arabia	Distribution of Medicines	**99%**	99%
Suez International Nitrate Company ("SINCO")	Arab Republic of Egypt	Production of Ammonium Nitrate	**100%**	100%
Chemical Company for Commercial Investment Limited ("CCCIL")	Kingdom of Saudi Arabia	Wholesale and retail trade in medicines, cosmetics, perfumes, beauty soups, medical tools, and other supplies	**100%**	100%
AJA Pharmaceuticals Industries Company Limited ("AJA Pharma Company")	Kingdom of Saudi Arabia	Manufacturing pharmaceutical products, packaging and storing of medicines, and other medical products.	**100%**	100%
Saudi Chemical Company Limited ("SCCL")	Kingdom of Saudi Arabia	Establishment, manufacturing & Ownership of explosive Factories	**100%**	100%
Saha Al-Hayya Holding Company ("Sihavita")	Kingdom of Saudi Arabia	Managing, investing the funds, owning real estate, providing loans and guarantees and financing, and owning industrial rights of subsidiaries of the holding company.	**100%**	100%
Zand Al-Teenemiya Holding Company ("XND")	Kingdom of Saudi Arabia	Managing, investing the funds, owning real estate, providing loans and guarantees and financing, and owning industrial rights of subsidiaries of the holding company.	**100%**	100%

2 BASIS OF PREPARATION

These interim condensed consolidated financial statements have been prepared in accordance with International Accounting Standard, Interim Financial Reporting" ("IAS 34") as endorsed in Kingdom of Saudi Arabia and other standards and pronouncements that are endorsed by the Saudi Organization for Chartered and Professional Accountants ("SOCPA").

The interim condensed consolidated financial statements do not include all the information and disclosures required for a complete set of annual consolidated financial statements and therefore, should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2025.

An interim period is considered an integral part of the whole fiscal year, however, the results of operations for the interim periods may not be a fair indication of the results of the full year operations.

Basis of measurement and functional currency
These interim condensed consolidated financial statements have been prepared under the historical cost convention, unless stated otherwise in the below accounting policies. Employee defined benefit obligations are recognized at the present value of the future obligations using the projected unit credit method. Also, these interim condensed consolidated financial statements have been prepared using the accrual basis of accounting and will continue to operate on the going concern basis.

These interim condensed consolidated financial statements are presented in thousands of Saudi Riyals ("﷼") unless stated otherwise. ("﷼") is also the functional currency of the Company. ("﷼") is the presentation currency of the Group and all its subsidiaries except for SINCO which uses United States Dollar ("USD") as its functional currency.

2.1 SUMMARY OF MATERIAL ACCOUNTING POLICY INFORMATION

The accounting policies used in the preparation of these interim condensed consolidated financial statements are consistent with those used in the preparation of the Group's annual financial statements for the year ended 31 December 2025, except for the application of new accounting policies below effective from 1 January 2026.

The Group has not early adopted any new standards, interpretations or amendments that have been issued but are not yet effective.

Many of the amendments and interpretations are effective for the first time in 2026, but do not have any material impact on the Group's interim condensed consolidated financial statements. The nature and impact of these changes are disclosed below.

Classification and Measurement of Financial Instruments – Amendments to IFRS 9 and IFRS 7
In May 2024, the IASB issued Amendments to IFRS 9 and IFRS 7, Amendments to the Classification and Measurement of Financial Instruments (the Amendments). The Amendments include:

▪ Clarifications of the requirements for recognition and derecognition of financial assets and financial liabilities. In particular, a financial liability is derecognised on the 'settlement date' and an accounting policy choice is introduced (if specific conditions are met) to derecognise financial liabilities settled using an electronic payment system before the settlement date.

▪ Additional guidance on how the contractual cash flows for financial assets with environmental, social and corporate governance (ESG) and similar features should be assessed
▪ Clarifications on what constitute 'non-recourse features' and what are the characteristics of contractually linked instruments.
▪ The introduction of disclosures for financial instruments with contingent features and additional disclosure requirements for equity instruments classified at fair value through other comprehensive income (OCI).

The amendments did not have impact on the Group's interim condensed consolidated financial statements

2 BASIS OF PREPARATION (continued)

2.1 SUMMARY OF MATERIAL ACCOUNTING POLICY INFORMATION (CONTINUED)

Annual Improvements to IFRS accounting Standards – Volume 11
In July 2024, the IASB issued nine narrow scope amendments as part of its periodic maintenance of IFRS accounting standards. The amendments include clarifications, simplifications, corrections or changes to improve consistency in IFRS 1 First-time Adoption of International Financial Reporting Standards, IFRS 7 Financial instruments: Disclosure and its accompanying Guidance on implementing IFRS 7, IFRS 9 Financial Instruments, IFRS 10 Consolidated Financial Statements and IAS 7 Statements of Cash Flows.

The amendments are effective for annual reporting periods beginning on or after 1 January 2026. When applying the amendments, an entity cannot restate comparative information.

The amendments did not have impact on the Group's interim condensed consolidated financial statements.

Contracts Referencing Nature -dependent Electricity – Amendments to IFRS 9 and IFRS 7

In December 2024, the IASB issued Amendments to IFRS 9 and IFRS 7 - Contracts Referencing Nature-dependent Electricity. The amendments apply only to contracts that reference nature-dependent electricity, and they:

- Clarify the application of the 'own-use' requirements for in-scope contracts.
- Amend the designation requirements for a hedged item in a cash flow hedging relationship for in -scope contracts
- Add new disclosure requirements to enable investors to understand the effect of these contracts on a company's financial performance and cash flows.

The amendments did not have impact on the Group's interim condensed consolidated financial statements.

New and amended standards and interpretations not yet effective
The new amended, issued standards and interpretations, which are not effective yet have not been adopted early by the Group and will be adopted on their effective date as applicable. The adoption of these standards and interpretations is not expected to have any material impact on the Group on the effective date, except IFRS 18, which the Group is currently evaluating the impact of its adoption on the financial statements.

Standard, Amendment or Interpretation	*Effective date*
- IFRS 18: Presentation and Disclosure in Financial Statements – Replaces IAS (1) Presentation of Financial Statements*	1 January 2027
- IFRS (19) - Subsidiaries without Public Accountability: Disclosures	1 January 2027
- IAS (21) The Effects of Changes in Foreign Exchange Rates - Translation to a Hyperinflationary Presentation Currency	1 January 2027
- Amendments to IFRS (10) and IAS (28): Sale or Contribution of Assets between an Investor and its Associate or Joint Venture	The effective date of this amendment is postponed indefinitely.

***IFRS 18 – Presentation and Disclosure in Financial Statements**

In April 2024, the International Accounting Standards Board issued IFRS 18 'Presentation and Disclosure in Financial Statements' ("IFRS 18"), which replaces IAS 1 Presentation of Financial Statements. IFRS 18, as endorsed in the Kingdom of Saudi Arabia, is effective for annual reporting periods beginning on or after 1 January 2027, with earlier application permitted, and is required to be applied retrospectively.

On adoption, the Group will restate the comparative period and will disclose a reconciliation for each line item in the statement of profit or loss and other comprehensive income between the restated amounts presented applying IFRS 18 and the amounts previously presented applying IAS 1.

2 BASIS OF PREPARATION (CONTINUED)

2.1 SUMMARY OF MATERIAL ACCOUNTING POLICY INFORMATION (CONTINUED)

***IFRS 18 – Presentation and Disclosure in Financial Statements (Continued)**

IFRS 18 introduces new requirements for the presentation of the statement of profit or loss and other comprehensive income, disclosure requirements for management-defined performance measures and enhanced principles for the aggregation and disaggregation of information in the financial statements and the notes. IFRS 18 does not change the recognition and measurement of items in the financial statements; accordingly, profit for the year, earnings per share and total equity are not affected. The Group has performed an initial assessment of the impact of IFRS 18 on its financial statements, the results of which are set out below. The assessment is ongoing and the expected impacts described below are preliminary and may change as the Group finalizes its implementation of IFRS 18.

a) Structure of the Statement of Profit or Loss

The standard is expected to result in changes to the presentation of certain line items and subtotals in the interim condensed consolidated statement of profit or loss namely operating, investing, financing, income tax and discontinued operations. This classification depends on the main business activities of the Group. Based on the Group's preliminary assessment and the nature of its main business activities performed to date, the Group expects changes to the current structure of interim condensed consolidated statement of profit or loss to result in:

- Finance Income: Finance income are mainly profits earned on short-term deposits which are currently reported as finance income in the interim condensed consolidated statement of profit or loss. These activities are incidental to the Group's operations and do not represent its principal business. Since investing in assets is not a specified main business activity of the Group, accordingly under IFRS 18, these incomes should be classified within the investing category of the interim condensed consolidated statement of profit or loss;

- Finance costs: Finance costs are mainly from Saudi Industrial Development Fund's financing, Islamic finance facilities and borrowings, lease liabilities recognized under IFRS 16 and employees' benefits obligations which together are currently reported as finance cost in the interim condensed consolidated statement of profit or loss. These financing arrangements support the Group's operating activities and do not represent a principal business activity. Under IFRS 18, these costs should be classified within the financing category of the interim condensed consolidated statement of profit or loss.

- Revaluation gain (loss) on derivative financial instruments: The Group holds several derivative financial instruments to mitigate the risk of fluctuations on interest and profit rates in relation to borrowings of the Group. Since these instruments supports the group in managing interest rate risk, the revaluation gain (loss) due to change in fair value of derivative financial instruments will be presented under the financing category under IFRS 18 classification.

- Foreign exchange differences: Foreign exchange differences are currently presented in other income (expenses) – net in the interim condensed consolidated statement of profit or loss. Under IFRS 18, foreign exchange differences will generally be classified in the same category of the statement of profit or loss as the income and expenses from the items that gave rise to those foreign exchange differences.

b) Management-defined performance measures

Management-defined performance measures (MPMs) are subtotals of income and expenses used in public communications outside the financial statements that communicate to users management's view of an aspect of the financial performance of the entity as a whole. The Group will be required to disclose specific information about MPMs in a single note in the financial statements.

The Group is in process to determine which public communications should be considered when identifying MPMs. MPMs relate to the same reporting period as the financial statements. Therefore, MPMs disclosed by the Group, following adoption of IFRS 18, will be determined based on public communications issued by the Group

2 BASIS OF PREPARATION (CONTINUED)

2.1 SUMMARY OF MATERIAL ACCOUNTING POLICY INFORMATION (CONTINUED)

***IFRS 18 – Presentation and Disclosure in Financial Statements (Continued)**

c) Principles of aggregation and disaggregation

IFRS 18 provides enhanced principles on how to group information in the financial statements (i.e. the primary financial statements and the notes). It also introduces guidance on labelling and describing items presented in the primary financial statements or disclosed in the notes.

The Group is assessing the grouping of items on the basis of similar and dissimilar characteristics. Based on this assessment, it will present line items in the primary financial statements that provide useful structured summaries and disclose additional material information in the notes.

d) Consequential amendments

IFRS 18 introduces consequential amendments to IAS 7, which require entities to use the newly defined operating profit subtotal as the starting point for the statement of cash flows when presenting operating cash flows under the indirect method. The Group currently uses profit for the year/period as the starting point of the reconciliation to cash flows from operating activities. Certain adjusting items included in the reconciliation will change as a result of the new starting point.

The Group will continue to evaluate the impact of IFRS 18 and will provide further information in future reporting periods as the implementation assessment progresses

2.2 ACCOUNTING ESTIMATES AND ASSUMPTIONS AND JUDGMENTS

The preparation of the Group's interim condensed consolidated financial statements requires management to make judgments, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, the accompanying disclosures, and the disclosure of contingent liabilities, at the reporting date. However, uncertainty about these assumptions and estimates could result in outcomes that may require a material adjustment to the carrying amount of the asset or liability affected in the future. These estimates and assumptions are based upon experience and various other factors that are believed to be reasonable under the circumstances and are used to judge the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised or in the revision period and future periods if the changed estimates affect both current and future periods.

As at 30 September 2026, management believes that all sources of estimation uncertainty remain similar to those disclosed in the Group's annual consolidated financial statements for the year ended 31 December 2025. The current geopolitical developments (refer to 2.3 below) has not materially impacted the significant accounting judgements, estimates and assumptions as at and for the period ended 30 September 2026 and management will continue to monitor the situation and any changes required will be reflected in future reporting periods.

2.3 ONGOING REGIONAL GEOPOLITICAL DEVELOPMENTS

The Group continues to monitor the regional geopolitical developments and their potential impact, while supply chain has been impacted in terms of cost and availability, these developments have not had a material impact on Group's financial statements for the period ended 30 September 2026. However, given the evolving nature of the situation, the potential impact on the Group's business and financial performance will continue to be assessed on future reporting dates as further escalation or prolonged continuation of the conflict could potentially affect its business.

3 PROPERTY, PLANT AND EQUIPMENT, CAPITAL WORK IN PROGRESS AND INTANGIBLE ASSETS AND GOODWILL

3.1 PROPERTY, PLANT AND EQUIPMENT

The following is a summary of the movement in property, plant and equipment:

	30 September 2026 ***﷼ '000*** ***(Unaudited)***	*31 December 2025* *﷼ '000* *(Audited)*
Cost		
Balance at the beginning of the period/year	**1,235,269**	1,195,469
Additions	**10,163**	18,254
Disposals	**-**	(1,650)
Transfers from capital work in progress	**348,857**	23,196
Balance at the end of the period/year	**1,594,289**	1,235,269
Accumulated depreciation		
Balance at the beginning of the period/year	**625,923**	577,378
Charge for the period/year	**36,212**	49,201
Disposals	**-**	(656)
Balance at the end of the period/year	**662,135**	625,923
Net book value	**932,154**	609,346

3.2 CAPITAL WORK IN PROGRESS

The following is a summary of the movement in Capital work in progress:

	30 September 2026 ***﷼ '000*** ***(Unaudited)***	*31 December 2025* *﷼ '000* *(Audited)*
Balance at the beginning of the period/year	**497,145**	499,111
Additions	**55,654**	22,339
Transfers to property, plant and equipment	**(348,857)**	(23,196)
Transfers to intangible assets	**(6,994)**	(1,109)
Balance at the end of the period/year	**196,948**	497,145

Capital work in progress mainly represents costs incurred in establishing the Group's explosives factory in Riyadh, in addition to other projects carried out to comply with security regulations. During the period, the Group has completed the construction works and secured clearance on TNT production line of its explosives factory in Riyadh. Accordingly, capital work-in-progress amounting to ﷼ 348.9 million has been capitalized during the period. The remaining production lines are expected to commence production during the year.

Refer to Note 13.2 the capital commitments related to these projects.

3 PROPERTY, PLANT AND EQUIPMENT, CAPITAL WORK IN PROGRESS AND INTANGIBLE ASSETS AND GOODWILL (CONTINUED)

3.3 INTANGIBLE ASSETS AND GOODWILL

The following is a summary of the movement in Intangible assets:

	New brand key money ﷼ *'000*	*Computer software* ﷼ *'000*	*Goodwill* ﷼ *'000*	*Other intangible assets* ﷼ *'000*	*Total* ﷼ *'000*
Cost					
As at 31 December 2025 (audited)	**12,500**	**53,235**	**469,807**	**138,820**	**674,362**
Additions	**-**	**2,485**	**-**	**-**	**2,485**
Transfer from CWIP		**6,994**			**6,994**
As at 30 September 2026 (unaudited)	**12,500**	**62,714**	**469,807**	**138,820**	**683,841**
Amortization and impairment					
As at 31 December 2025 (audited)	**12,500**	**27,200**	**-**	**14,345**	**54,045**
Amortization	**-**	**3,366**	**-**	**4,166**	**7,532**
As at 30 September 2026 (unaudited)	**12,500**	**30,566**	**-**	**18,511**	**61,577**
Net book value					
As at 30 September 2026 (unaudited)	**-**	**32,148**	**469,807**	**120,309**	**622,264**

	New brand key money ﷼ *'000*	*Computer software* ﷼ *'000*	*Goodwill* ﷼ *'000*	*Other intangible assets* ﷼ *'000*	*Total* ﷼ *'000*
Cost					
As at 31 December 2024 (audited)	12,500	49,516	469,807	138,820	670,643
Additions	-	2,610	-	-	2,610
Transfer from CWIP	-	1,109	-	-	1,109
As at 31 December 2025 (audited)	12,500	53,235	469,807	138,820	674,362
Amortization and impairment					
As at 31 December 2024 (audited)	12,500	23,073	-	8,792	44,365
Amortization	-	4,127	-	5,553	9,680
As at 31 December 2025 (audited)	12,500	27,200	-	14,345	54,045
Net book value					
As at 31 December 2025 (audited)	-	26,035	469,807	124,475	620,317

4 DERIVATIVE FINANCIAL INSTRUMENTS

Derivative financial instruments designated at fair value through profit or loss represent a portfolio of profit rate swaps having maturity date 2028 with three-month variable interest rate and prevailing interest rates between the Saudi banks ("SIBOR"). These derivatives do not meet the criteria for hedge accounting. The nominal value of the contracts as at 30 September 2026 was ﷼ 700 million (31 December 2025: ﷼ 700 million) and the fair value of derivatives represents a net asset of ﷼ 5.95 million (31 December 2025: asset of ﷼ 329 thousand). The change in the fair value of derivatives represents a gain of ﷼ 5.619 million for the nine-month period ended 30 September 2026 (30 September 2025: loss of ﷼1.414 million).

5 TRADE RECEIVABLES

	30 September 2026 ﷼ '000 (Unaudited)	*31 December 2025 ﷼ '000 (Audited)*
Trade receivables	**3,172,698**	2,912,816
Allowance for expected credit loss	**(322,853)**	(281,342)
Total	**2,849,845**	2,631,474

Trade receivables from Saudi government and government related institutions represent 64% of the total trade receivables as of 30 September 2026 (31 December 2025: 66% of the total trade receivables). These institutions have a strong credit rating in the Saudi market.

6 TRANSACTIONS WITH RELATED PARTIES

Related parties represent shareholders, directors, key management personnel of the Group, and entities controlled, jointly controlled, or significantly influenced by such parties. The transactions with the related parties are made on terms approved by the Board of Directors of the Group. The Group and the related parties transact with each other in the ordinary course of business. As at period and yearend, all transactions between subsidiaries were eliminated.

6.1 COMPENSATION AND BENEFITS OF KEY EXECUTIVES

The following represent the compensation of the executives:

	For the three-month period ended 30 September		*For the nine-month period ended 30 September*	
	2026 ﷼ '000 (unaudited)	*2025 ﷼ '000 (unaudited)*	***2026 ﷼ '000 (unaudited)***	*2025 ﷼ '000 (unaudited)*
Expenses and remuneration of the Board of Directors	**1,350**	1,350	**4,050**	4,050
Short-term benefits and remuneration	**2,729**	3,098	**13,833**	15,929
Post-employment benefits	**219**	198	**439**	546

6.2 BALANCES OF RELATED PARTIES

The following table shows the total amount of transactions made with related parties during the three and nine-month periods ended on 30 September 2026 and 30 September 2025, in addition to the balances with related parties as at 30 September 2026 and 31 December 2025:

			For the three-month period ended 30 September		*For the nine-month period ended 30 September*		*Balance as at*	
Name of related party	*Relationship*	*The nature of the transaction*	***2026 ﷼ '000 (unaudited)***	*2025 ﷼ '000 unaudited)*	***2026 ﷼ '000 (unaudited)***	*2025 ﷼ '000 (unaudited)*	***30 September 2026 ﷼ '000 (unaudited)***	*1 December 2025 ﷼ '000 (audited)*
Amounts due from a related party								
*Care Supply Chain for Logistics Services **	*Joint venture*	*Affiliate services*	**-**	-	**3,816**	119	**3,816**	6,942

* Care Supply Chain for Logistic Services Company Ltd. (the "Joint Venture" and "CSC") is a joint venture in which the Group has a joint control and partners' resolutions are adopted unanimously as per the Joint Venture's Articles of Association, with an ownership interest of 50%. The Joint Venture has been incorporated as per Saudi Regulations and registered in Riyadh under commercial registration number 1010846387 on 17 Jumada Al-Ula 1444H (11 December 2022) with a share capital at an amount of ﷼ 500 thousand divided into 500 shares of ﷼ 1000 each. The objective of the Joint Venture is to provide transportation services, loading, unloading, warehousing and distribution. The Group's share in the joint venture is accounted for under equity method.

7 SHARE CAPITAL

As at 30 September 2026, the share capital of the Company consists of 843,200,000 shares with nominal value of ﷼ 1 per share aggregating to ﷼ 843,200,000 (31 December 2025: 843,200,000 shares with nominal value of ﷼ 1 per share aggregating to ﷼ 843,200,000).

8 LOANS AND BORROWINGS

8.1 SAUDI INDUSTRIAL DEVELOPMENT FUND'S FINANCING

The long-term loans were obtained by two subsidiaries of the Group from Saudi Industrial Development Fund ("SIDF") to meet the Group's capital expenditure. The first loan was obtained by AJA Pharmaceuticals Industries Limited ("AJA Pharma") during 2016 and amounted to ﷼ 157.5 million, of which the full amount of the facility has been utilized as at 30 September 2026 (31 December 2025: ﷼ 157.5 million). The second loan was obtained by Saudi Chemical Company Limited ("SCCL") during 2020 and amounted to ﷼ 229 million, of which the full amount of the facility has been utilized as at 30 September 2026 (31 December 2025: ﷼ 229 million).

On 18 Jumada al-Ula 1447H corresponding to 6 November 2025, SCCL obtained an additional financing facility of ﷼ 50 million to support working capital requirements. Administrative fees of ﷼ 2.5 million were deducted upfront and are amortized over the term of the facility. The additional financing is repayable through a single payment after two years from the date of the agreement on 27 Jumada al-Alkhirah 1449H corresponding to 06 November 2027.

The loan to AJA Pharma is repayable in sixteen semi-annual installments starting from 15 Shawwal 1444 H (corresponding to 5 May 2024), while the loan to SCCL is repayable in fourteen semi-annual installments starting from 15 Rabi Al-Thani 1444 H (corresponding to 9 November 2022).

The loans from SIDF carried fixed commission charges of ﷼ 28.9 million, which have been paid upfront by the Group at the beginning of the loan term. The commission charges are being amortized over the terms of the loans. As at 30 September 2026, the unamortized balance amounted to ﷼ 6.157 million (31 December 2025: ﷼ 9.034 million).

The amortization of such qualified charges along with other finance costs of the loan are capitalized as part of the carrying value of the property, plant and equipment (during the construction period).

The agreements are secured promissory notes, and pledge of the subsidiaries' property, plant and equipment. The subsidiaries are required to comply with certain covenants under the loan facilities obtained.

The following represents a summary of information about the Saudi Industrial Development Fund's:

	30 September 2026 ﷼ '000 (Unaudited)	*31 December 2025 ﷼ '000 (Audited)*
Loans from Saudi Industrial Development Fund	**262,500**	315,500
Less: Unamortized processing fees	**(6,157)**	(9,034)
Present value adjustment	**(2,569)**	(4,039)
	253,774	302,427
Current	**58,298**	50,935
Non-current	**195,476**	251,492
	253,774	302,427

8 LOANS AND BORROWINGS (CONTINUED)

8.1 SAUDI INDUSTRIAL DEVELOPMENT FUND'S FINANCING (CONTINUED)

Movement in unamortized transaction costs are as follows:

	30 September 2026 ***﷼ '000*** ***(Unaudited)***	*31 December 2025* *﷼ '000* *(Audited)*
Balance at the beginning of the period/year	**9,034**	9,685
Additions during the period/year	**-**	2,500
Amortized during the period/year	**(2,877)**	(3,151)
Balance at the end of the period/year	**6,157**	9,034

8.2 SHORT-TERM ISLAMIC LOANS

The Group is using Islamic financing to finance its business operations. These facilities bear finance cost at SAIBOR plus a profit margin rates. The facilities are secured by promissory notes. The facilities agreement includes covenants requiring the maintenance of certain levels of financial ratios.

8.3 LONG TERM ISLAMIC LOANS

In June 2022, the Group acquired a long-term Islamic loan from a local bank in the amount of ﷼ 300 million to finance the construction of the subsidiary's factory. The loan is subject to SIBOR plus a profit margin. The loan is repayable in 6 years in quarterly installments after a grace period of two years.

Also, during June 2022, the Group acquired a long-term Islamic loan from a local bank in the amount of ﷼ 140 million to finance its acquisition of a pharmaceutical product's rights. The loan is subject to SIBOR plus a profit margin. The loan is repayable in equal 6 semi-annual installments with the last installment payable in December 2026 after a grace period of two year. The loan agreement includes covenants requiring the maintenance of certain levels of financial ratios.

9 REVENUE

	For the three-month period ended 30 September		***For the nine-month period ended 30 September***	
	2026 ***﷼ '000*** ***(Unaudited)***	*2025* *﷼ '000* *(Unaudited)*	***2026*** ***﷼ '000*** ***(Unaudited)***	*2025* *﷼ '000* *(Unaudited)*
Sale of goods	**1,673,254**	1,773,622	**5,200,761**	5,161,035
Rendering of services	**24,288**	14,450	**65,832**	36,378
	1,697,542	1,788,072	**5,266,593**	5,197,413
Government	**502,755**	633,910	**1,729,641**	1,880,443
Non-government	**1,194,787**	1,154,162	**3,536,952**	3,316,970
	1,697,542	1,788,072	**5,266,593**	5,197,413

Revenue is recognized in the interim condensed consolidated statement of profit or loss at a point in time when the service or product is deemed to have been delivered to the customer. Refer to Note 14 for the segment distribution of revenue.

10 ZAKAT AND INCOME TAX

Movement in Zakat and income Tax provision during the period/year

	30 September 2026 ***﷼ '000*** ***(Unaudited)***	*31 December 2025* *﷼ '000* *(Audited)*
As at the beginning period/year	**74,008**	63,820
Charged during the period/year	**41,028**	47,566
Paid during the period/year	**(46,447)**	(37,378)
As at the end of the period/year	**68,589**	74,008

Zakat and income tax provisions of ﷼ 41 million were recognized by the Group during the nine-month period ended 30 September 2026 (30 September 2025: ﷼ 35.1 million). The Company, SITCO Pharma, CCCIL, AJA Pharma and SCCL have filed their zakat declarations and obtained zakat certificates for the years up to 2019

The Group obtained the approval from Zakat, Tax and Customs Authority ("ZATCA") to submit consolidated zakat returns for the Company and the following subsidiaries: SCCL, AJA Pharma, and CCCIL starting from the year 2020. In addition, SITCO Pharma submits a separate zakat return. The Group has submitted its consolidated zakat returns for the years 2020 to 2025. No assessment has been raised by ZATCA for the years from 2020 to 2025 yet.

SITCO Pharma has filed its zakat declarations for the years up to 2025. During the period ended 30 September 2026, SITCO obtained the final zakat assessments for years 2020, 2021 and 2022 from ZATCA. The final zakat assessment did not result in any additional zakat liability. No assessment has been raised by ZATCA for the years from 2023 to 2025 yet.

INCOME TAX

The income tax expense payable by a foreign subsidiary, in accordance with the prevailing tax regulations in its country, for the period ended 30 September 2026 amounted to ﷼ 466 thousand (30 September 2025: ﷼ 1.4 million).

11 BASIC AND DILUTED EARNING PER SHARE

Earnings per share is computed using net profit for the period attributable to Shareholders of the Company based on the weighted average number of shares outstanding for the periods ended on 30 September 2026 and 2025 by 843,200,000 shares.

The diluted earnings per share are the same as the basic earnings per share as the Group does not have any dilutive instruments in issue.

The following table reflects the income for the year attributable to equity holders of the parent and share data used in the basic and diluted EPS computations:

	For the three-month period ended 30 September		***For the nine-month period ended 30 September***	
	2026 ***﷼ '000*** ***(Unaudited)***	*2025* *﷼ '000* *(Unaudited)*	***2026*** ***﷼ '000*** ***(Unaudited)***	*2025* *﷼ '000* *(Unaudited)*
Profit for the period attributable to equity holders of the parent	**64,590**	87,240	**232,365**	238,474
Weighted average number of ordinary shares	**843,200,000**	843,200,000	**843,200,000**	843,200,000
Basic and diluted earnings per share attributable to equity holders of the parent (﷼)	**0.08**	0.10	**0.28**	0.28

12 FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES

12.1 Fair value Hierarchy

Assets and liabilities measured at fair value in the interim condensed consolidated statement of financial position are grouped into three levels of fair value hierarchy. This grouping is determined based on the lowest level of significant inputs used in fair value measurement, as follows:

Level 1:Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3: Inputs for the asset or liability that are not based on observable market data (unobservable inputs).

All the financial assets and liabilities of the Company are carried at amortized cost except for derivative financial instruments which are classified as fair value through profit or loss.

12.2 Carrying amount vs Fair value

	Fair value measurement hierarchy	***30 September 2026 (Unaudited)***		*31 December 2025 (Audited)*	
		Carrying value	***Fair value***	*Carrying value*	*Fair value*
		﷼ '000	***﷼ '000***	***﷼ '000***	***﷼ '000***
Derivative financial instruments	Level 2	**5,948**	**5,948**	329	329

The derivative financial instrument is carried at fair value using valuation techniques, which employ the use of market observable inputs.

The Group considers that the carrying amount of trade receivables, amount due from a related party, other assets, cash and cash equivalents, Saudi Industrial Development Fund's financing, long-term Islamic loans, lease liabilities, short-term Islamic loans, trade payables, dividends payable, accrued expenses and other liabilities are a reasonable approximation of their fair value.

13 CONTINGENT LIABILITIES AND CAPITAL COMMITMENTS

13.1 CONTINGENT LIABILITIES

A) As at 30 September 2026, the Group had outstanding letters of guarantee amounting to ﷼ 297.9 million (31 December 2025: ﷼ 311 million), issued in the normal course of business of the Group. Moreover, as at 30 September 2026, the Group had outstanding letters of credit amounting to ﷼ 132.8 million (31 December 2025: ﷼ 213.4 million).

B) The Group has contingent liabilities from time to time relating to certain disputed matters, including claims from and against contractors, litigation and arbitration proceedings involving a variety of cases. These contingent liabilities arose in the normal course of business. The management believes and with the consulting of its legal consultant that no additional significant obligations are expected to be incurred from these potential claims.

13.2 COMMERCIAL AND CAPITAL COMMITMENTS

Capital commitments outstanding as at 30 September 2026, in respect of capital work in progress projects amounted to ﷼ 57.9 million (31 December 2025: ﷼ 15.1 million).

14 SEGMENTAL INFORMATION

For management purposes, the Group consists of business units according to the products and services it provides. The Group's operations are principally in the explosives, medicines and medical supplies and production of ammonium nitrate. Except for the information related to the production of ammonium nitrate segment that is located in the Arab Republic of Egypt, all other information is related to the business segments in the Kingdom of Saudi Arabia. All inter-company transactions within the appropriately reported segments have been eliminated.

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated on the basis of the statement of comprehensive income and is measured on a consistent basis based on profit or loss in the consolidated financial statements.

	Explosives	***Medicine and medical supplies***	***Production of ammonium nitrate***	***Head office***	***Eliminations / Adjustments***	***Total***
	﷼ '000	***﷼ '000***	***﷼ '000***	***﷼ '000***	***﷼ '000***	***﷼ '000***
As at 30 September 2026 (Unaudited)						
Segment assets	**1,118,905**	**5,396,847**	**89,547**	**3,487,596**	**(3,391,242)**	**6,701,653**
Segment liabilities	**769,556**	**3,652,257**	**59,826**	**956,695**	**(1,283,717)**	**4,154,617**
As at 31 December 2025 (Audited)						
Segment assets	1,026,636	4,811,562	86,423	3,054,359	(2,743,970)	6,235,010
Segment liabilities	670,760	3,309,391	55,496	671,503	(869,251)	3,837,899

	Explosives	***Medicine and medical supplies***	***Production of ammonium nitrate***	***Head office***	***Eliminations / Adjustments***	***Total***
	﷼ '000	***﷼ '000***	***﷼ '000***	***﷼ '000***	***﷼ '000***	***﷼ '000***
For the three-month period ended 30 September 2026 (Unaudited)						
Revenues	**117,046**	**1,578,780**	**1,716**	**-**	**-**	**1,697,542**
Intersegment revenue	**-**	**34,633**	**12,681**	**-**	**(47,314)**	**-**
Net revenues	**117,046**	**1,613,413**	**14,397**	**-**	**(47,314)**	**1,697,542**
Segment comprehensive income (loss)	**(474)**	**64,015**	**(732)**	**64,591**	**(62,279)**	**65,121**

	Explosives	*Medicine and medical supplies*	*Production of ammonium nitrate*	*Head office*	*Eliminations / Adjustments*	*Total*
	﷼ '000	*﷼ '000*	*﷼ '000*	*﷼ '000*	*﷼ '000*	*﷼ '000*
For the three-month period ended 30 September 2025 (Unaudited)						
Revenues	108,455	1,671,588	8,029	-	-	1,788,072
Intersegment revenue	-	49,190	11,376	-	(60,566)	-
Net revenues	108,455	1,720,778	19,405	-	(60,566)	1,788,072
Segment comprehensive (loss) income	12,035	78,605	(484)	86,692	(89,472)	87,376

14 SEGMENTAL INFORMATION (CONTINUED)

	Explosives ﷼ *'000*	*Medicine and medical supplies* ﷼ *'000*	*Production of ammonium nitrate* ﷼ *'000*	*Head office* ﷼ *'000*	*Eliminations / Adjustments* ﷼ *'000*	*Total* ﷼ *'000*
For the nine-month period ended 30 September 2026 (Unaudited)						
Revenues	**308,723**	**4,949,090**	**8,780**	**-**	**-**	**5,266,593**
Intersegment revenue	**-**	**129,649**	**29,090**	**-**	**(158,739)**	**-**
Net revenues	**308,723**	**5,078,739**	**37,870**	**-**	**(158,739)**	**5,266,593**
Segment comprehensive income	**(6,529)**	**243,524**	**(1,205)**	**232,366**	**(233,911)**	**234,245**

	Explosives ﷼ *'000*	*Medicine and medical supplies* ﷼ *'000*	*Production of ammonium nitrate* ﷼ *'000*	*Head office* ﷼ *'000*	*Eliminations / Adjustments* ﷼ *'000*	*Total* ﷼ *'000*
For the nine-month period ended 30 September 2025 (Unaudited)						
Revenues	284,774	4,880,188	32,451	-	-	5,197,413
Intersegment revenue	-	123,957	37,116	-	(161,073)	-
Net revenues	284,774	5,004,145	69,567	-	(161,073)	5,197,413
Segment comprehensive income	14,604	229,577	1,271	241,223	(246,223)	240,452

15 DIVIDENDS

The Board of Directors, in its meeting held on 23 Ramadhan 1447H (corresponding to 12 March 2026) recommended the distribution of cash dividend of ﷼ 0.10 per share amounting ﷼ 84.320 million for financial year 2025 which was approved by the shareholders in Company's Ordinary General Assembly meeting held on 26 Thul-Qi'dah 1447H (corresponding to 13 May 2026). The dividend was paid during the period ended 30 September 2026.

16 COMPARATIVE FIGURES

Certain comparative figures for the previous year have been reclassified to conform to the current year's presentation.

	2025 As previously Reported ﷼ *'000*	*Reclassification* ﷼ *'000*	*2025 Amount as per FS* ﷼ *'000*
Cost of revenues	4,523,184	27,336	4,550,520
Selling and distribution expenses	150,356	(27,336)	123,020

17 SUBSEQUENT EVENTS

The management believes no material events have occurred subsequent to the reporting date that would require adjustment to, or disclosure in, these interim condensed consolidated financial statements for the three and nine-month periods ended 30 September 2026.

18 APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

These interim condensed consolidated financial statements have been approved by the Board of Directors of the Company on 25 Jumada al-Ula 1448H (corresponding to 5 November 2026).